- Masimo Corporation (NASDAQ:MASI) is scheduled to report its latest earnings, with analysts forecasting an earnings per share (EPS) of $1.41 and revenue of approximately $398.65 million.
- Stockholders recently approved the strategic acquisition of Masimo by Danaher Corporation (NYSE: DHR), a move expected to drive future growth within Danaher’s Diagnostics segment.
Masimo Corporation (NASDAQ:MASI) is a global medical technology company that specializes in noninvasive patient monitoring technologies. The company develops a wide range of devices used in healthcare settings. It operates in the competitive medical instruments sector, where it faces rivals such as DexCom (NASDAQ: DXCM).
Investors are focused on Masimo Corporation as it is scheduled to report its earnings on May 5th, 2026. Wall Street analysts estimate an earnings per share (EPS) of $1.41. EPS is a company’s profit divided by its shares. For the quarter, revenue is estimated to be approximately $398.65 million.
This earnings report follows a significant corporate development. On May 1, 2026, stockholders approved the company’s acquisition by Danaher Corporation (NYSE: DHR). As highlighted by Business Wire, CEO Katie Szyman stated the deal provides “compelling value” and supports Masimo Corporation’s future growth within Danaher’s Diagnostics segment.
The revenue expectations are backed by the performance of Masimo Corporation’s core products. As highlighted by Zacks Investment Research, a recent study found its SET pulse oximetry technology is highly accurate in newborns of all skin tones. This finding may encourage stronger clinical adoption and support sales growth.
